Company Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers.
Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies.
Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc.
The company was incorporated in 2014 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2014 |
| IPO Date | Apr 3, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 124 |
| CEO | Dr. Kimberly Lynn Blackwell M.D. |
Contact Details
Address: 1359 Broadway, Suite 801 New York, New York 10018 United States | |
| Phone | (212) 433-3791 |
| Website | zentalis.com |
Stock Details
| Ticker Symbol | ZNTL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001725160 |
| CUSIP Number | 98943L107 |
| ISIN Number | US98943L1070 |
| Employer ID | 82-3607803 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kimberly Lynn Blackwell M.D. | Chief Executive Officer and Director |
| Cameron S. Gallagher M.B.A. | Co-Founder, President and Director |
| Melissa B. Epperly M.B.A. | Chief Financial Officer and Treasurer |
| Andrea Paul J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Mark Lackner Ph.D. | Chief Scientific Officer |
| Dr. Diana F. Hausman M.D. | Chief Medical Officer and Director |
| Kimberly Freeman | Chief Strategy Officer |
| Dr. Kyle Rasbach Ph.D., Pharm.D. | Chief Business Officer |
| Dr. Adrian Jubb M.D., Ph.D. | Executive Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2024 | 8-K | Current Report |
| Apr 9, 2024 | 8-K | Current Report |
| Feb 29, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 29, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 27, 2024 | 10-K | Annual Report |
| Feb 27, 2024 | 8-K | Current Report |
| Feb 15, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |